Neurologic Drugs : Antiepileptics
IDEPA1 “Depakine Lyophilized injection” 400 mg/vial
ODEPA2 “Depakine EC tablet” 200 mg/tab
ODEPA3 “Depakine sol’n” 200 mg/ml; 40 ml/bot
ODEPA4 “Depakine Chrono FC tablet” 500 mg/tab
適應症：
IDEPA1：無法以口服途徑控制之癲癇。
ODEPA2：泛發性與局部癲癇症、兒童抽搐或兒童熱性抽搐、行為失常並伴有癲癇症者。
ODEPA3：癲癇之大發作、小發作、混合血液型及顳葉癲癇。
ODEPA4：癲癇之大發作、小發作、混合型及顳葉癲癇，躁病。
Usual dose:
Adult (≧10 yrs): 10-15 mg/kg/day, may increase dosage 5-10 mg/kg/week to achieve optimal clinical response (max. 60 mg/kg/day or less with a therapeutic range of 50-100 mcg/ml).
Contraindication:
Hepatic disease or significant hepatic dysfunction, known urea cycle disorders.
Adverse effect:
Common: peripheral edema, alopecia, rash, increased/loss of appetite, weight gain, abdominal pain, constipation, diarrhea, indigestion, nausea, vomiting, ecchymosis, asthenia, backache, amnesia, ataxia, feeling nervous, headache, insomnia, somnolence, tremor, amblyopia, blurred vision, diplopia, nystagmus, tinnitus, depression, disturbance in thinking, mood swings, bronchitis, dyspnea, pharyngitis, respiratory tract infection, rhinitis, fever, influenza.
Serious: palpitations, tachycardia, hyperammonemia, hematemesis, dose-related thrombocytopenia, immune hypersensitivity reaction, coma, hyperammonemia-induced, hyperammonemic encephalo, ototoxicity – deafness.
健保使用規範：Sodium valproate注射劑 (如Depakine Lyophilized Injection)(89/7/1、93/2/1、93/6/1、102/10/1)
限癲癇症病患使用，且符合以下其中之一項者使用：
1.對phenytoin注射劑無效或無法忍受phenytoin副作用且無法口服valproic acid之病患。
2.癲癇連續發作(Seizure clusters) 之病患。
3.癲癇重積狀態(Status epilepticus) 之病患。